Tarsus Pharmaceuticals (NASDAQ:TARS) Coverage Initiated at Oppenheimer
Oppenheimer began coverage on shares of Tarsus Pharmaceuticals (NASDAQ:TARS – Free Report) in a research report released on Monday morning. The firm issued an outperform rating and a $75.00 price target on the stock. A number of other equities research analysts have also recently weighed in on TARS. Jefferies Financial Group increased their price target […]
Oppenheimer began coverage on shares of Tarsus Pharmaceuticals (NASDAQ:TARS – Free Report) in a research report released on Monday morning. The firm issued an outperform rating and a $75.00 price target on the stock. A number of other equities research analysts have also recently weighed in on TARS. Jefferies Financial Group increased their price target […]
